ACE Inhibitors News and Research

RSS
ACE inhibitors act to reduce hypertension by interfering with the conversion of angiotensin I to artery-constricting angiotensin II. Blocking the production of angiotensin II results in arterial vasodilation and an accompanying reduction in blood pressure. ACE inhibitors currently are recommended as first-line therapy for hypertension in certain patient populations, because of their safety and efficacy.
Study shows ActiveHealth's VBID programs increase adherence to medications

Study shows ActiveHealth's VBID programs increase adherence to medications

New report illustrates why cardiovascular disease is under-recognized and under-treated in women

New report illustrates why cardiovascular disease is under-recognized and under-treated in women

Sinobiopharma's solid dosage Perindopril production facility receives Chinese SFDA approval

Sinobiopharma's solid dosage Perindopril production facility receives Chinese SFDA approval

New issue from Annals of Internal Medicine

New issue from Annals of Internal Medicine

High blood pressure drugs may be useful in preventing and treating diabetic retinopathy

High blood pressure drugs may be useful in preventing and treating diabetic retinopathy

Authors explain why health care reform initiative should include CER

Authors explain why health care reform initiative should include CER

American Diabetes Association recommends A1C test for diagnosing diabetes and identifying pre-diabetes

American Diabetes Association recommends A1C test for diagnosing diabetes and identifying pre-diabetes

Alternative therapy for hypertension

Alternative therapy for hypertension

Free medications to people after heart attack will increase length of their life

Free medications to people after heart attack will increase length of their life

European Commission approves MICARDIS medication for CV protection

European Commission approves MICARDIS medication for CV protection

MICARDIS receives Health Canada approval to reduce the risk of non-fatal stroke

MICARDIS receives Health Canada approval to reduce the risk of non-fatal stroke

Carvedilol in combination with ACE inhibitors may benefit cardiac patients

Carvedilol in combination with ACE inhibitors may benefit cardiac patients

NHLBI-supported research shares new strategies on hypertension, heart defect and air pollution

NHLBI-supported research shares new strategies on hypertension, heart defect and air pollution

Publicly released report cards do not appear to improve hospitals' performance, says new study

Publicly released report cards do not appear to improve hospitals' performance, says new study

Drug therapy offers substantial cost savings than angioplasty

Drug therapy offers substantial cost savings than angioplasty

Mayo Clinic Health Letter provides treatment options for people with heart disorders

Mayo Clinic Health Letter provides treatment options for people with heart disorders

Self-care tips for hemorrhoids from Mayo Clinic

Self-care tips for hemorrhoids from Mayo Clinic

Canadian cardiologists, oncologists team up to fight breast cancer

Canadian cardiologists, oncologists team up to fight breast cancer

Boehringer Ingelheim receives European CHMP positive opinion for MICARDIS

Boehringer Ingelheim receives European CHMP positive opinion for MICARDIS

Canadian Cardiovascular Society to honor University of Alberta medical researcher

Canadian Cardiovascular Society to honor University of Alberta medical researcher

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.